Horizon Illumination Lab Optics, Co. Ltd.
Technology Development for the Fundamental Innovation and Clinical Deployment of Opto-Diagnostics

Program name

Deep-Tech Startups Support Program

Business Plan

Opto-Diagnostics is a unique technology that enables pre-treatment, single-cell–level evaluation of the efficacy of molecular targeted therapies. By substituting part of its molecular structure, the platform can be adapted to virtually all cancers treated with small-molecule targeted agents. We are developing two business applications based on this platform, i.e., (1)Drug Discovery Support and (2) Drug Sensitivity Testing for Physicians. We are working with KOLs toward obtaining regulatory approval of Opto-Diagnostics as a Software as a Medical Device (SaMD).

Research Outline

This project will accelerate commercialization by expanding the repertoire of Opto-Diagnostics agents and advancing development toward regulatory approval for chronic myeloid leukemia (CML). To that end, we aim to achieve the following proof-of-concept (PoC) milestones:

1. Development of new Opto-Diagnostics agents via a bottom-up approach
2. Development using a top-down approach (OBBA method)
3. Development of automated image analysis software
4. Evaluation of drug efficacy in EGFR-mutant non-small cell lung cancer
5. Analytical and performance testing for regulatory submission for CML approval

• Download this page（153KB）